REGISTER NOW

January 23-25 2018, San Francisco

www.tumor-models-sf.com



SAN FRANCISCO 2018

TUMOR MODELS

Harnessing Clinical Insights to Improve Preclinical & Translational Outcomes

Increase the Predictive Value of Preclinical and Translational Research for Cancer Immunotherapies



Expert speakers include:

Rafael Cubas Barcelli
Scientist
Genentech

Shon Green
Scientist, Preclinical Development
Eureka Therapeutics

Dan Rock
Executive Director
Amgen

Cinthia Pastuskovas
Senior Scientist
Amgen

Barbara Joyce-Shaikh
Associate Principal Scientist
Merck

Kolin Hribar
CEO and Founder
Cypre, Inc.

Lead Partner:
The Jackson Laboratory
Leading the search for tomorrow's cures

Hosting Partner:
CrownBio
CONNECTING SCIENCE TO PATIENTS

Expertise Partner:
MITRA BIOTECH

Program Partner:
CHAMPIONS ONCOLOGY

Spotlight Partners:
pharmatest
Bioresearch
Advancing Your Preclinical Oncology

Exhibitors:
studylog®
Animal Study Workflow Software

Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com Tumour Models

hansonwade

Welcome Back to the 2nd Tumor Models San Francisco 2018

Discover the application & data of more predictable and humanized models to enhance the translation of novel cancer therapies from preclinical research to patient.

Tumor Models San Francisco returns a year wiser for the 2nd Summit, bringing together industry and academic leaders from the preclinical and translational oncology worlds. Succeed in producing more predictive and clinically relevant preclinical research when developing your Immuno-Oncology therapies.

At Tumor Models San Francisco, learn how to best recapitulate the human tumor microenvironment in your preclinical models. Develop, characterize, and effectively use immuno competent models that create predictive and translatable research for your immunotherapy drug candidates. Learn how those around you are harnessing the power of adoptive cell therapy and CRISPR to strengthen their drug development.

Learn how to harness the most predictive preclinical research packages to forward your adoptive cell therapies to improve your clinical success. Discover the novel preclinical models creating excitement in the preclinical oncology field, and how to utilize them to bridge the translational gap.

Kick off 2018 powerfully by joining the most assured conference for tackling the challenges presented when creating preclinical data packages for the development of your immuno and combination therapies. Leave San Francisco feeling content and rejuvenated with learnings from data-driven case studies, ready to optimize the clinical success of your drug discoveries.

Hear What Previous Attendees Have To Say:

"I really enjoyed the speakers and the networking. It was great to exchange ideas at the round table discussion and meet other people with similar concerns about tumor models"
Shawnya Michaels, VP, Scientific Affairs, Escend Pharmaceuticals, Inc., Past attendee, Tumor Models San Francisco 2017

"This conference was amazing! The collaborations I created are priceless. Thanks so much!"
Kiera Rycaj, Assistant Professor, Roswell Park Cancer Institute, Past attendee, Tumor Models San Francisco 2017

6 Key Takeaways from Tumor Models San Francisco this year

1. Discover **Cypre's** Innovative use of 3D Tumor Models Built with Scalable Bioprinting Technology to Improve Cancer Drug Development



2. Learn How to Utilise CRISPR to Accurately Model Clinical Tumor Subtypes Through Insights From **Cedars-Sinai Medical Center**

3. Understand How **Takeda** Leverage the Data from Pre-Clinical Studies and Minimize Translational Failures

4. Discover How **Genentech** are Understanding T cell Exhaustion in Common Syngeneic Tumor Models to Better Define T-Cell Functionality



5. Understand How to Overcome the Limitations of Immune-Compromised Mice with **Eureka's** Perspective

6. Learn How to Test Reprogrammed TILs in *In Vivo* Mice Model with Insights from the **University of Pittsburgh**

Expert Speakers

Rafael Cubas Barcelli
Scientist
Genentech

Shon Green
Scientist, Preclinical Development
Eureka Therapeutics

Svetlana Sadekova
Senior Principal Scientist, Head Experimental and Translational Pathology
Merck

Dan Rock
Executive Director
Amgen

Barbara Joyce-Shaikh
Associate Principal Scientist
Merck

Kolin Hribar
CEO and Founder
Cypre, Inc.

Rafael Ponce
Scientific Director
Juno Therapeutics

Cinthia Pastuskovas
Senior Scientist
Amgen

Dr. Abhishek Srivastava
Assistant Professor
University of Pittsburgh

Mithun Khattar
Immuno-oncology lead
Takeda

Joshua Breunig
Assistant Professor, Board of Governors Regenerative Medicine Institute, Department of biomedical Sciences
Cedars-Sinai Medical Center

Karen Spratt
Research Scientist
Seattle Children's

James Keck
Senior Director for the Clinical Lab & In Vivo Pharmacology Services
The Jackson Laboratory

Davy Ouyang
Senior Scientific Director, Global Oncology
Crown Bioscience

Dylan Daniel
Director - Scientific Development
MI Bioresearch

Neal Goodwin
Vice President, Corporate Research & Development
Champions Oncology

Mari Suominen
Research Director
Pharmatest

Andrew Rhim
CPRIT Scholar in Cancer Research, Associate Director for Translational Research in Pancreatic Cancer Research
MD Anderson Cancer Center

Mark Paris
Associate Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Maria Hristopoulos
Translational Oncology
Genentech

Simon Knott
Assistant Professor & Associate Director, Center for Bioinformatics and Functional Genomics
Cedars Sinai Medical Center

Conference Day One | Wednesday, January 24th 2018

8.00 Registration

9.00 Chairperson's Opening Remarks

Enhancing Preclinical Strategies for Developing Cancer Immunotherapies Through Next Generation Preclinical Research

James Keck
Senior Director for the Clinical Lab & In Vivo Pharmacology Services
The Jackson Laboratory

9.10 Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform
- The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization
- Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX tumors

Joshua Breunig
Assistant Professor, Board of Governors Regenerative Medicine Institute, Department of biomedical Sciences
Cedars-Sinai Medical Center, and David Geffen School of Medicine, UCLA

9.40 Preclinical Modeling of Diverse Brain Tumor Subtypes via Single-Copy Somatic Transgenesis and CRISPR Genome Editing
- Overview of novel genetic methodologies for rapid, autochthonous tumor modeling
- Strategies for combining single-copy somatic transgenesis with CRISPR genome editing to generate patient-derived mutation signatures in mouse models to accurately model clinical tumor subtypes in a "personalized" manner
- Examples of preclinical studies investigating strategies to impede tumor growth and development by immunotherapy, metabolic targeting, and therapeutic mimicry

Mithun Khattar
Immuno-oncology lead
Takeda

10.10 Pre-clinical Modeling of Immune Responses to Cancer: From Bench-Side to Clinical Outcomes
- Fundamental differences in immune composition, tumor microenvironments and disease progression between mice and humans
- Preclinical models in immune-oncology: what translates and what doesn't
- How to leverage the data from pre-clinical studies and minimize translational failures

Davy Ouyang
Senior Scientific Director, Global Oncology
Crown Bioscience

10.40 Developing Checkpoint Target Humanized Models for Preclinical Efficacy Assessment
- Lack of animal models for efficacy evaluation of human therapeutic antibodies for cancer Immunotherapies
- HuGEMM models, expressing chimeric checkpoint targets with human extracellular domains, allow the evaluation of specific human biological therapies *in vivo*

11.10 Speed Networking

11.40 Morning Refreshments

Kolin Hribar
CEO & Founder
Cypre inc.

12.10 Utilizing 3D Tumor Models Built With Scalable Bioprinting Technology to Improve Cancer Drug Development
- A new type of 3D bioprinting technology for screening
- Patient-derived tumor testing for precision medicine
- Assaying immuno-oncology in 3D

Enhancing the Power of Predictive Preclinical Research to Forward the Clinical Success of Your Adoptive Cell Therapies

Dr. Abhishek Srivastava
Assistant Professor
University of Pittsburgh

12.40 T Cell Co-Stimulation: A Potent Pathway for Improved Adoptive Cell Therapy
- Tumor Infiltrating Lymphocytes (TIL) therapy) and its impact on the melanoma patients
- Ex-vivo reprogramming of T cells for improved therapy
- Learn how to test these reprogrammed TILs in *In vivo* mice model

Rafael Cubas Barcelli
Scientist
Genentech

13.10 Understanding T cell Exhaustion in Common Syngeneic Tumor Models
- Co-expression of inhibitory the receptors PD1/LAG3/TIM3 enriches for highly activated CD8 T cells in established syngeneic tumor models
- Reduced functionality of TILs is observed in PD1- population rather than PD1+ CD8 population.
- Caution must be exercised when using inhibitory receptor expression alone to define T cell functionality in commonly used syngeneic tumor models

13.40 Lunch and Networking

Shon Green
Scientist, Preclinical Development
Eureka

14.40 Optimizing *In Vivo* Models for the Development of Autologous T cell Therapies

- What models are being utilized to evaluate efficacy of engineered T-cell therapies?
- How do we overcome the limitations of immune-compromised mice?
- Characterizing your T cells in vivo to extract correlates with efficacy

Neal Goodwin
Vice President, Corporate Research & Development
Champions Oncology

15.10 Advanced PDX Tumor Biology Platforms for Drug Advancement

- Harnessing large collections of PDX models for more resolute efficacy predictions and the discovery of new therapeutic targets, resistance mechanisms, and biomarker signatures of response
- How robust systems of myeloid engraftment, including hematopoietic stem cells for immune-oncology modeling and AML engraftment for high throughput multipatient in vivo screens, have now provided expanded PDX screening with a wider scope of therapeutic agents
- Advancement of coupled-PDX trials, where clinical trials are combined with companion PDX studies to help guide follow-on trial design

15.40 Afternoon Refreshments and Networking

Svetlana Sadekova
Senior Principal Scientist, Head Experimental and Translational Pathology
Merck

16.10 Human Tissue Based Preclinical Models for Biomarker Discovery and Translational Research

- Understand the need for translational strategies to guide indication selection
- Understand mechanisms of resistance and identify biomarkers of response
- Highlighting the importance of understanding human tumor microenvironment
- Utilizing human tissues for pre-clinical and clinical translational research

Barbara Joyce-Shaikh
Associate Principal Scientist, Immunoncology
Merck

16.40 Humanized Mouse Models for Drug Discovery Research

- Development of humanized *In Vivo* models to develop IO therapeutics
- Explore the advantages and limitations of humanized vs syngeneic systems
- Leveraging humanized systems for deciphering mechanism of action and clinical translation

17.10 Interactive Tumor Models San Francisco Roundtable Session

In this session, you will have the opportuinty to catch up on the latest advancements within the field and learn from your fellow colleagues in this interactive format to address your challenges faced when working in the clinical oncology space

1. **Harnessing Next Generation Humanized Mice Models to Increase the Predictability of Your Preclinical Research**

2. **Which Models Provide the Best Platform for The Development of Your T cell Therapies**

3. **How Well Can Learnings be Translated Between In Vitro and In Vivo Models**

18.10 Chairperson's Closing Remarks

The Jackson Laboratory
Leading the search for tomorrow's cures

18.15 Drinks Reception Hosted by The Jackson Laboratory

Conference Day Two | Thursday, January 25th 2018

8.30 **Breakfast and Networking**

9.00 **Chairperson's Opening Remarks**

Enhancing the Power of Predictive Preclinical Research to Forward the Clinical Success of Your Adoptive Cell Therapies

Mark Paris
Associate Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

9.10 **Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology**

- Mitra Biotech has developed and clinically validated fully human ex-vivo platform technology (CANscript™)
- CANscript ™ uses patient material (tumor, autologous ligands and immune cells) to explore the mechanism of and predict efficacy for clinically-directed compounds across several drug classes
- This talk will explore how CANscript can better enable your translational efforts and aid in advancing your highest potential candidate into successful clinical trials

Cinthia Pastuskovas
Senior Scientist
Amgen

9.40 **Characterization of ADME Properties of Novel Protein Therapeutics**

- Next generation protein therapeutics are engineered in an attempt to improve the efficacy of monoclonal antibody therapeutics in the oncology setting
- Designing multifunctional therapeutics for enhanced pharmacologic activity or improved target selectivity
- Altering the targeting and/or activity of a molecule can concomitantly lead to novel and unanticipated ADME properties and pharmacokinetics for the therapeutic
- Characterization of the stability and overall disposition of bispecific antibodies and antibody-cytokine fusion proteins to help guide engineering and selection of lead candidates

Dan Rock
Executive Director
Amgen

10.10 **Understanding Preclinical Pharmacokinetics and ADME of Bispecific T-cell Engagers**

- Bispecific T-cell engagers represent novel class of protein molecules wherein engineering efforts can impact pharmacokinetics and pharmacologic activity.
- Understand the importance of preclinical experimental design criteria for translation to the clinic.

Mari Suominen
Research Director, Cancer Models
Pharmatest

10.40 **Novel Bone Metastasis Models in Syngeneic and Humanized Mice**

- Importance of tumor microenvironment
- Testing antitumor efficacy in bone metastasis models
- Immunotherapy and bone

11.10 **Morning Refreshments**

Rafael Ponce
Sr. Director, Preclinical Sciences
Juno Therapeutics

11.50 **Strategies For Using Models in Engineered T Cell Research and Development**

- Animal models as a pivotal tool for evaluating engineered T cells (CAR or engineered TCR), including to benchmark construct design, evaluate combinatorial opportunities, and inform safety issues and mitigation strategies.
- Rationale and case studies, including the current state-of-the art of rodent and non-human primate to inform pharmacology of engineered T cells
- Experience in using these models for informing pathogenesis and mitigation strategies for neurotoxicity and cytokine release syndrome.

 **Dylan Daniel** Director, Scientific Development **MI Bioresearch**	**12.20 Utilization of Murine Breast Cancer Models in Preclinical Immuno-Oncology Pharmacology** • Pros and Cons of the 4T1 Mammary Cancer Model • Characteristics of Alternative Syngeneic Breast Models • Responses of a New Model to Checkpoint Inhibition and T Cell Costimulation
 **Maria Hristopoulos** Translational Oncology **Genentech**	**12.40 Optimizing Preclinical Models for The Development of T Cell Dependent Bispecific (TDBs) Antibody Therapies Targeting Solid Tumors** • Overview of TDB antibodies • Limitations of using syngeneic and GEMM in vivo models to demonstrate antitumor efficacy of TDBs in solid tumors • Utilizing the huPBMC transfer model in NSG mice to demonstrate efficacy and establish preclinical therapeutic index of TDB antibodies
	13.10 Lunch and Networking
 **Karen Spratt** Research scientist **Seattle Children's**	**14.10 Multiplexing CAR T cell therapy** • Bispecific CARs targeting 2 antigens in ALL • Multiplexing CAR with regulatory CARs • How to track multiple CARs In Vitro and *In Vivo*
 **Andrew Rhim** CPRIT Scholar in Cancer Research, Associate Director for Translational Research in Pancreatic Cancer Research **MD Anderson Cancer Center**	**14.40 Evaluating Preclinical Predictions for the Development of Combinations with Targeted Therapies & Immunotherapies** • Describing models used and key considerations for experimental design • Model responses and predictability of combination efficacy
	15.10 Chairperson's Closing Remarks
	15.15 Close of the 2nd Annual Tumor Models San Francisco Summit

PART OF THE TUMOR MODELS EVENT SERIES

BOSTON TUMOR MODELS
Harnessing Clinical Insights to Improve Preclinical & Translational Outcomes

LONDON 2017 TUMOUR MODELS
Increasing the Value of Preclinical & Translational Research

WORKSHOP

Pre-Conference Workshop Day | Tuesday, January 23rd 2018

Workshop A

Guide: Utilise Humanized Mice for Your Immuno-Oncology Preclinical Research For Increased Translational Success

9:00am - 12:00pm

Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.

In this workshop you will find:

- Evidence that humanized NSG™ and NSG™-SGM3 mice can support the growth of allogeneic human tumors
- Human tumors respond to standard-of-care chemotherapeutics and to immune check-point inhibitors clinically proven to initiate cytotoxic activity towards the tumor
- Tumor-bearing, humanized NSG™ and NSG™-SGM3 mice are a new and valuable preclinical testing platform for immunooncology

Workshop Leader
James Keck
Senior Director, In Vivo Pharmacology & Clinical Lab Services
The Jackson Laboratory

James Keck's expertise is in the therapeutic areas of oncology, virology, and inflammatory and metabolic diseases. During his career he has led teams working in animal pharmacology, assay development, drug discovery, target identification, protein expression and translational research.

Workshop B

Models and methods for studying tumor heterogeneity and metastases

13:00pm - 16:00pm

The deadliest cancers are often characterized by significant intratumoral heterogeneity, which is often increased in metastases or recurrent tumors. Comprehending the mechanisms of heterogeneity and the patterns of divergence in tumor subtypes will be a significant factor in designing the next generation of anti-tumor therapeutics, including immunotherapies and small molecule inhibitors.

In this workshop you will learn:

- Emerging findings in primary patient samples and models regarding the striking heterogeneity in high-grade tumors
- New methodologies for characterizing the emergence of intratumoral heterogeneity through the creation of lineage trees
- State-of-the-art techniques for comparing metastatic populations to the original tumor

Workshop Leader
Joshua Breunig, Assistant Professor, Board of Governors, Regenerative Medicine Institute, Department of biomedical Sciences, **Cedars-Sinai Medical Center**

Joshua Breunig, PhD, is an Assistant Professor at Cedars-Sinai Medical Center with a joint appointment in the Department of Medicine at the David Geffen School of Medicine at UCLA. Dr. Breunig received his Ph.D. from Yale University. Currently, he investigates the transcriptional regulation of neural precursor cells (NPCs) in the brain, specifically exploring the pathways governing the transformation of NPCs into brain tumor progenitors. Using a next generation brain tumor models, his lab introduces patient-specific mutations to create "personalized" tumors in immunocompetent animal models. Dr. Breunig is supported by funding from the American Cancer Society, and NIH/NCI.

Workshop Leader
Simon Knott, Assistant Professor & Associate Director, Center for Bioinformatics and Functional Genomics, **Cedars Sinai Medical Center**

Dr. Knott combines computational biology and functional genomics to elucidate the molecular mechanisms that drive cancer progression. Work in his laboratory is focused on three main areas: heterogeneity in cancer cell populations and how it impacts disease outcome, hetero-cellular interactions that allow cancer cells to manipulate the tumor microenvironment to evade therapy, and the development of novel computational and molecular tools to study disease progression.

Partners

Lead Partner

The Jackson Laboratory
Leading the search for tomorrow's cures

The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute-designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development.

www.jax.org

Hosting Partner

CrownBio
CONNECTING SCIENCE TO PATIENTS

Our mission is to provide the "gold-standard" collection of well-characterised models and services for drug discovery to help our clients reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic. Crown Bioscience, Inc. is a Preclinical CRO with expertise in the disease areas of Oncology and Metabolic Disease. We are known for the breadth and quality of our in vitro and in vivo models, as well as our ability to help clients quantify the real efficacy and pharmacological profile of their candidate before they move into the clinic.

www.crownbio.com

Expertise Partner

MITRA BIOTECH™

Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our unique CANscript™ platform delivers powerful, individualized treatment response predictions —with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and enhance drug discovery.

www.mitrabiotech.com

Program Partner

CHAMPIONS ONCOLOGY

Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncology professionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Champions Personalized TumorGrafts™ empower patients and physicians using an in vivo xenograft mouse avatar-based diagnostic model that has shown to be predictive of a patients' clinical response.

www.championsoncology.com

Spotlight Partner

pharmatest

Pharmatest Services Ltd is a CRO offering preclinical efficacy services for the pharmaceutical industry. We offer bothin vitro and in vivo models in the fields of oncology and skeletal diseases. In oncology we have special expertise in clinically predictive orthotopic and metastasis models, and especially models of bone metastasis.

www.pharmatest.com

Spotlight Partner

MI Bioresearch
Advancing Your Preclinical Oncology

MI Bioresearch (MI), a preclinical oncology service provider, offers in vitro services, oncology pharmacology, in vivo imaging, and focal radiation to support research programs. Our team explores the effects of your drugs and biologics using both human and syngeneic models and multi-modality imaging systems. MI provides you with decision-driving data to help advance your drug candidate toward the next cancer research breakthrough. One Focus. One Purpose. Oncology Research.

www.mibioresearch.com

Exhibitor

studylog®
Animal Study Workflow Software

Studylog's Animal Study Workflow Software® is designed for biomedical animal research and provides features for the design, planning, execution, analysis, and reporting of animal studies in a standardized, highly efficient manner, while protecting data integrity. Reducing many labs' study-related labor by half, Studylog automates and streamlines the entire animal study process, making it asier, f aster and cheaper, so researchers have more time and resources to get their job done.

www.studylog.com

BECOME A PARTNER

Diane McKenna
Commercial Director, Tumor Models
T:+1 212 537 5898
E: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.tumor-models-sf.com/register/

Tel: +44 (0)203 141 8700

Email: register@hansonwade.com

Team Discounts*

10% discount - 3 delegates

15% discount - 4 delegates

20% discount - 5 or more delegates

Check Ts&Cs before booking

ACADEMICS	Register and Pay before Friday, October 13 **(SAVE $500)**	Standard Price
Conference + 2 Workshop (Save $200)	$2,097	$2,597
Conference + Workshop (Save $100)	$1,698	$2,198
Conference Only	$1,299	$1,799
Workshop Only	$499	

PHARMA, BIOTECH AND DRUG DEVELOPERS	Register and Pay before Friday, October 13 **(SAVE $700)**	Standard
Conference + 2 Workshop (Save $200)	$2,997	$3,697
Conference + Workshop (Save $100)	$2,398	$3,098
Conference Only	$1,799	$2,499
Workshop Only	$699	

SOLUTION PROVIDER	Register and Pay before Friday, October 13 **(SAVE $700)**	Standard
Conference + 2 Workshop (Save $200)	$3197	$3897
Conference + Workshop (Save $100)	$2898	$3598
Conference Only	$2299	$2999
Workshop Only	$699	



VENUE

Hotel Kabuki, 1625 Post Street, San Francisco, CA 94115

For further information or assistance, please visit visit http://www.jdvhotels.com/hotels/california/san-francisco-hotels/hotel-kabuki/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers.

Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry.

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Team discounts cannot be applied to academic pricing

Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH